U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07485751) titled 'Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study' on March 16.
Brief Summary: The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant schizophrenia. It will also learn about the preliminary efficacy of the exosomes. The main questions it aims to answer are:
Is the safety of the exosomes enough for participants? Is the feasibility of nasal deliv...